Blog

Insight

The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer – Dana-Farber’s Breast Oncology Center

Photo from Dana-Farber’s Breast Oncology Center/X

Feb 15, 2024, 18:29

The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X/Twitter:

”The MARGOT study led by Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium is optimizing preoperative therapy for Stage II-III HER2+ breast cancer, comparing paclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab. For more information call 877-338-7425 or visit the website.”

Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer cancer Dana-Farber’s Breast Oncology Center MARGOT OncoDaily Oncology paclitaxel/margetuximab/pertuzumab paclitaxel/trastuzumab/pertuzumab preoperative therapy Translational Breast Cancer Research Consortium

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Tedros Adhanom Ghebreyesus: The WHO Academy has opened its door to the world

Special Coverage